VasoREACTivity Testing With Intravenous SILdenafil in Patients With Precapillary Pulmonary Hypertension
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
Sildenafil is a selective pulmonary vasodilator; in patients with a special kind of pulmonary
hypertension it is approved for treatment. The trial seeks to find out, whether the acute
response to this treatment (= vasoreactivity testing) given intravenously is effective and
allows prediction of therapy success during a following oral treatment.